Pneumonia Vaccine Market to Witness Robust Expansion throughout the Forecast 2019-2026 | Panacea Biotec Limited, Pfizer Inc

UPDATE AVAILABLE ON-DEMAND

According to the report by Allied Market Research, the global pneumonia vaccine market is estimated to register a CAGR of 5% from 2018 to 2025. The research helps leading players and startups to devise new strategies based on current market trends and changing dynamics. Competitive landscape is mentioned in the report based on business segments, products portfolio, and strategic moves & developments of leading market players. Detailed segmentation assists in determining growing segments and determining further steps to capitalize on lucrative segments. Regional landscape is helpful in determining opportunities and driving factors of each region and taking further steps.

Pneumonia is a lung infection that occurs in one or both the lungs caused by bacteria, virus, or fungi; however, bacterial pneumonia is the most common form occurring in adults.

Click Here To Access Free Sample Report @ https://www.alliedmarketresearch.com/request-sample/2730

Pneumonia results in inflammation in the air sacs (known as alveoli) of the lungs, which results in filling the alveoli with fluid (pus cells), thus causing breathing problems. Pneumococcal disease is common in young children, but older adults are at greatest risk of serious pneumococcal infections and even death.

Pneumonia vaccines are primarily administered to children less than 2-years old and adults aged 65 years and older. This vaccine helps individuals provide immunization against 13 types of pneumococcal bacteria that causes infection in the lungs.

The key factors that drive the growth of the global pneumonia vaccine market include increase in prevalence of pneumonia across the globe, rise in government focus on immunization programs for pneumonia, and introduction of novel pneumococcal vaccines such as PCV10. However, longer timelines required for pneumonia vaccine production and high costs associated with development of such vaccines restrain the market growth. Development of protein-based combination pneumococcal vaccines is expected to offer lucrative opportunities for the expansion of this market during the forecast period.

Based on type, pneumococcal conjugate vaccine (PCV) is expected to maintain its dominant (more than half of the market share in 2017) position during the analysis period as it is been widely prescribed as compared to pneumococcal polysaccharide vaccine (PPV).

Based on product, the Prevnar 13 segment held the major market share in 2017 and is expected to dominate the market throughout the forecast period, owing to the wide usage and its efficiency in pneumonia prevention.

Inquire Before Buying @ https://www.alliedmarketresearch.com/purchase-enquiry/2730

Based on distribution channel, the distribution partner companies segment held majority of the market share in 2017, owing to the wide coverage of the private entities. This segment is expected to dominate the market during the forecast period due to majority of private vaccines purchases which are comparatively expensive are distributed from these companies. Hence, the distribution partner companies hold larger share.

Based on sector, the private sector dominates the overall market for pneumonia vaccines and is expected to dominate the market throughout the forecast period due to the higher prices of the vaccine in the private market.

North America accounted for nearly three-fifth of the global market in 2017 and is expected to remain dominant throughout the forecast period. This is attributed to the higher prevalence in the developing countries such as India and China, increase in government healthcare expenditure, rise in demand for better healthcare, and surge in number of childbirths in the region. Moreover, government support and development of protein-based combination pneumococcal vaccines are the factors expected to present new growth opportunities to the players in this market

The Major Key Players Are:

Glaxosmithkline plc., LG Chem Ltd., Merck & Co., Inc., Panacea Biotec Limited, Pfizer Inc., Pnuvax Incorporated, Serum Institute of India Pvt. Ltd., Shenzhen Kangtai Biological Products Co., Ltd. (Beijing Minhai Biotechnology Corporation Limited), SK Bioscience, and Walvax Biotechnology Co., Ltd.

Access Full Report @ https://www.alliedmarketresearch.com/pneumonia-vaccine-market

Contact:

David Correa
Portland, OR, United States
USA/Canada (Toll Free): +1-800-792-5285, +1-503-894-6022, +1-503-446-1141
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1(855)550-5975
help@alliedmarketresearch.com
Web: https://www.alliedmarketresearch.com

About Us

Allied Market Research (AMR) is a market research and business-consulting firm of Allied Analytics LLP, based in Portland, Oregon. AMR offers market research reports, business solutions, consulting services, and insights on markets across 11 industry verticals. Adopting extensive research methodologies, AMR is instrumental in helping its clients to make strategic business decisions and achieve sustainable growth in their market domains. We are equipped with skilled analysts and experts, and have a wide experience of working with many Fortune 500 companies and small & medium enterprises.

This release was published on openPR.